{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:33Z","timestamp":1793330793922,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the prevalence and clinicopathologic associations of FGFR-altered urinary tract carcinomas in institutions incorporating reflex testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Next-generation sequencing was prospectively performed on urinary tract carcinomas for the detection of FGFR1-4 alterations at 2 tertiary care centers (2021-2025), using the Oncomine Comprehensive Assay (OCA) v3 DNA and OCA Plus RNA. Reflex testing was conducted on metastatic and\/or advanced (pT3\/4) carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 366 patients (239 lower tract carcinomas, 72 upper tract carcinomas, and 55 metastases). Median age was 72.5 years (range, 36-97). Fifty-nine (16.1%) tumors were FGFR-altered. Forty-nine (13.4%) patients with actionable FGFR alterations (33 FGFR3 mutations, 13 FGFR3 fusions, and 3 FGFR2 mutations) were all 55 years or older (P\u2005=\u2005.097). The prevalence of actionable FGFR alterations was significantly higher in upper vs lower tract carcinomas (23.8% vs 13.8%, P\u2005=\u2005.007) and in lung metastases vs other metastatic sites (57.1% vs 10.4%, P\u2005=\u2005.002). A higher frequency was also seen in metastases vs primary tumors (16.4% vs 12.9%), although this difference did not reach statistical significance (P\u2005=\u2005.482). Actionable FGFR alterations were observed in urothelial carcinoma not otherwise specified (40\/261) and in urothelial carcinoma with squamous differentiation (6\/43), micropapillary features (2\/11), or nested features (2\/7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The detection rate for FGFR1-4 alterations in a real-world, dual-institution cohort of urinary tract carcinomas was reported.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf108","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T11:24:47Z","timestamp":1756725887000},"page":"861-869","source":"Crossref","is-referenced-by-count":6,"title":["Reflex somatic testing for the detection of\n                    <i>FGFR<\/i>\n                    alterations in urinary tract carcinomas: A dual-institutional experience"],"prefix":"10.1093","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1363-2127","authenticated-orcid":false,"given":"Ngoc-Nhu Jennifer","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Anatomic Pathology, Precision Diagnostics & Therapeutics Program, Sunnybrook Health Sciences Centre , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Olkhov-Mitsel","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Precision Diagnostics & Therapeutics Program, Sunnybrook Health Sciences Centre , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Craddock","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Anatomic Pathology, Precision Diagnostics & Therapeutics Program, Sunnybrook Health Sciences Centre , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A","family":"Flood","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, The Ottawa Hospital , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R","family":"Downes","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Anatomic Pathology, Precision Diagnostics & Therapeutics Program, Sunnybrook Health Sciences Centre , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"2","key":"2026010814424354200_CIT0001","first-page":"203","article-title":"Cancer statistics, 2024 [published correction appears","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"2026010814424354200_CIT0002","volume-title":"EAU Guidelines Office, Arnhem, The Netherlands.","author":"EAU Guidelines","year":"2025"},{"key":"2026010814424354200_CIT0003","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","article-title":"Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience","volume":"108","author":"Yafi","year":"2011","journal-title":"BJU Int"},{"key":"2026010814424354200_CIT0004","doi-asserted-by":"publisher","first-page":"17588359211047352","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2026010814424354200_CIT0005","volume-title":"Bladder Cancer: NCCN Guidelines Version 1.2025","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026010814424354200_CIT0006","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Cancer Res."},{"key":"2026010814424354200_CIT0007","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res."},{"key":"2026010814424354200_CIT0008","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"2026010814424354200_CIT0009","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med."},{"key":"2026010814424354200_CIT0010","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med."},{"key":"2026010814424354200_CIT0011","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol."},{"key":"2026010814424354200_CIT0012","author":"Food and Drug Administration","year":"2025"},{"key":"2026010814424354200_CIT0013","author":"Government of Canada","year":"2020"},{"key":"2026010814424354200_CIT0014","author":"Cancer Care Ontario","year":"2025"},{"key":"2026010814424354200_CIT0015","author":"Food and Drug Administration","year":"2024"},{"key":"2026010814424354200_CIT0016","author":"Canada\u2019s Drug Agency","year":"2025"},{"key":"2026010814424354200_CIT0017","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn."},{"key":"2026010814424354200_CIT0018","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol."},{"key":"2026010814424354200_CIT0019","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1158\/0008-5472.can-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"2026010814424354200_CIT0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer [published correction appears in","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"2026010814424354200_CIT0021","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol."},{"key":"2026010814424354200_CIT0022","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"L\u00f3pez-Knowles","year":"2006","journal-title":"Cancer Res."},{"key":"2026010814424354200_CIT0023","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/path.4017","article-title":"CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma","volume":"227","author":"Rebouissou","year":"2012","journal-title":"J Pathol."},{"key":"2026010814424354200_CIT0024","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/his.13063","article-title":"Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway","volume":"70","author":"Downes","year":"2017","journal-title":"Histopathology."},{"key":"2026010814424354200_CIT0025","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar","year":"2003","journal-title":"Cancer Res."},{"key":"2026010814424354200_CIT0026","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol."},{"key":"2026010814424354200_CIT0027","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature."},{"key":"2026010814424354200_CIT0028","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/his.12473","article-title":"Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer","volume":"66","author":"Fischbach","year":"2015","journal-title":"Histopathology."},{"key":"2026010814424354200_CIT0029","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026010814424354200_CIT0030","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026010814424354200_CIT0031","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med."},{"key":"2026010814424354200_CIT0032","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2026010814424354200_CIT0033","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [published correction appears in","volume":"25","author":"Abou-Alfa","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026010814424354200_CIT0034","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2021-148103","article-title":"A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood."},{"key":"2026010814424354200_CIT0035","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol."},{"key":"2026010814424354200_CIT0036","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep."},{"key":"2026010814424354200_CIT0037","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-24-2015","article-title":"Characterization of FGFR alterations and activation in patients with high-risk non-muscle-invasive bladder cancer","volume":"30","author":"Eisner","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026010814424354200_CIT0038","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/cam4.262","article-title":"FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder","volume":"3","author":"Guancial","year":"2014","journal-title":"Cancer Med"},{"key":"2026010814424354200_CIT0039","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.juro.2014.06.026","article-title":"FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases","volume":"193","author":"Turo","year":"2015","journal-title":"J Urol."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/6\/861\/64714258\/aqaf108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/6\/861\/64714258\/aqaf108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:42:49Z","timestamp":1767901369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/164\/6\/861\/8287259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,16]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf108","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,16]]}}}